Bruce E Lewis,Jeanine M Walenga
Bruce E Lewis
Prior to initiation of the ARG-911 and ARG-915 clinical trials, there was no optimal replacement for heparin anticoagulation in patients with heparin-induced thrombocytopenia (HIT) type II. These prospective, historical controlled studies w...
Marian P LaMonte
Marian P LaMonte
Evidence for the potential use of direct thrombin inhibition in the treatment of acute stroke is reviewed. Reduction of secondary microthrombi and improved regional collateral cerebral blood flow is the proposed mechanism of action of throm...
Andrew N Nicolaides
Andrew N Nicolaides
Direct thrombin inhibitors inactivate thrombin without the need for antithrombin and some inactivate not only thrombin but also fibrin-bound thrombin. Hirudin has been shown to be more effective than low-dose unfractionated heparin and low ...
John L McGregor
John L McGregor
Thrombin is a multifunctional serine protease, which is involved in blood coagulation and thrombosis, inflammation and wound repair in tissue injury. Its role in the amelioration of inflammatory tissue injury has been investigated. Protease...
Development of argatroban as an anticoagulant and antithrombin agent in Japan [0.03%]
日本研发艾拉普酶为抗凝血及抗凝集药物
Hidenobu Ikoma
Hidenobu Ikoma
Argatroban is a synthetic direct thrombin inhibitor which has been used in Japan for three indications, namely, chronic arterial occlusion, acute cerebral thrombosis and hemodialysis in AT-deficient patients or in patients with decreased AT...
Fritz Markwardt
Fritz Markwardt
Progress in molecular biology has stimulated interest in the structure and function of thrombin. It has improved our understanding of its central role in thrombogenesis and has clarified the molecular events of inhibitor binding. This devel...
Jeanine M Walenga
Jeanine M Walenga
Argatroban is a small molecule direct thrombin inhibitor. The main attributes of this synthetic drug are its rapid onset of anti-thrombin action, rapid reversibility of its anticoagulant effect, potent inhibition of clot-bound thrombin, abs...
Current developments in antithrombotic therapy: the role of antithrombin agents [0.03%]
抗凝治疗的现状及抗凝血酶的新药研发方向
H K Breddin
H K Breddin
Hirudin, the specific thrombin inhibitor from medicinal leeches, is now produced by recombinant technology. r-Hirudin and to a lesser extent polyethyleneglycol-coupled hirudin (PEG-hirudin) have been used in many clinical trials. Hirudin ha...
Thrombosis and antiphospholipid antibodies in non-SLE patients: predictive value of antiphosphatidylserine antibodies [0.03%]
C Biron-Andréani,C Mallol,C Vergnes et al.
C Biron-Andréani et al.